ECTRIMS

Ozanimod Shows Long-Term Safety, Efficacy in Open-Label Extension

September 18, 2020

Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.

Asaff Harel, MD: Risk Factors for Severe COVID-19 Infection in Multiple Sclerosis

September 17, 2020

The neurologist at Lenox Hill Hospital detailed the findings of his observational study that looked at patterns of COVID-19 infections in patients with multiple sclerosis.

Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD

September 17, 2020

Two posters presented at MDS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.

Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MS

September 16, 2020

The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.

Tau Levels May Predict Early Disability, Worse Prognosis in MS

September 15, 2020

Data show that higher CSF tau levels at diagnosis correlated with worse disability independent of age, though no such associations were identified with amyloid-beta.

Ponesimod Linked to Low Levels of Disease Activity in Relapsing Multiple Sclerosis

September 14, 2020

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.